mabcure inc (MBCI:OTC US)
mabcure inc (MBCI) Snapshot
|
Open
$0.0064
|
Previous Close
$0.0064
|
|
|
Day High
$0.01
|
Day Low
$0.0064
|
|
|
52 Week High
05/18/12 - $0.05
|
52 Week Low
01/25/13 - $0.0050
|
|
|
Market Cap
643.6K
|
Average Volume 10 Days
16.6K
|
|
|
EPS TTM
$-0.01
|
Shares Outstanding
64.4M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
mabcure inc (MBCI) Related Businessweek News
No Related Businessweek News Foundmabcure inc (MBCI) Details
MabCure Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure Inc. in January 2008 to reflect its new business plan. MabCure Inc. was founded in 2006 and is based in White Plains, New York.
mabcure inc (MBCI) Key Developments
On November 13, 2012, Dr. Amnon Gonenne resigned from the Board of Directors of the MabCure, Inc. and Mr. Dov Weinberg resigned as Chief Financial Officer. Dr. Gonenne and Mr. Weinberg do not serve on any committees of the Board of Directors. The resignations were not the result of any disagreement with the Company relating to the company's operations, policies, or practices.
On October 19, 2012, Dr. David Frank and Ms. Vered Kaplan resigned from the Board of Directors of MabCure, Inc. Dr. Frank and Ms. Caplan do not serve on any committees of the Board of Directors. The resignations were not the result of any disagreement with the company relating to the company's operations, policies, or practices.
On September 20, 2012, the board of directors of the MabCure, Inc. provided Amnon Gonenne, the company's president and chief executive officer, with ninety days prior written notice of termination from his position as president and CEO of the company. Mr. Gonenne will continue to serve as a member of the company's board of directors. On September 11, 2012, Mr. Charles Tackney, the company's chief scientific officer, informed the company that he was resigning from his position as CSO, effective in ninety days. Mr. Tackney's resignation is for personal reasons, and is not the result of any disagreement with the company relating to the company's operations, policies, or practices.
| Recently Viewed | |||
| MBCI:US | $0.01 USD | +0.0036 |  |
| Company | Last | Change | |
| No competitor information is available for MBCI. | |||
| View Industry Companies | |||
Industry Analysis
MBCI
Industry Average
| Valuation | MBCI | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 0.8x |
|
| Price/Book | 0.1x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
Post a JobJobs
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
- New York, NY | New York UniversityPosted: Apr 19
Sponsored Financial Commentaries
Sponsored Links
To contact MABCURE INC, please visit www.mabcure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
